A promising new therapy for patients with acromegaly resistant to commercial available SRA is pasireotide, a multireceptor-targeted somatostatin analog with high affinity for 4 of the 5 somatostatin receptor subtypes (sst), including sst2 and sst5, which are the most prevalent sst on GH-secreting pituitary adenomas. Here, GH1 is linked to acromegaly.